SBIR/STTR Research Award
BOMBESIN ANTAGONISTS
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1992Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Peptide Technolgies Corp.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
RECENT BOMBESIN AND GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONISTS HAVE BEEN DEMONSTRATED TO B E QUITE POTENT IN INHIBITING THE EFFECTS OF BOMBESIN IN PANCREATIC ACINAR CELLS, BRAIN MEMBRANES, SWISS 3T3 FIBROBLASTS, AND HUMAN SMALL CELL LUNG CARCINOMA (SCLC). HOWEVER, THESE ANTAGONISTS DO NOT DISPLAY COMPARABLE HIGH POTENCY IN INHIBITING THE PROLIFERATION OF HUMAN SMALL CELL LUNG CARCINOMA. CERTAIN BOMBESIN ANTAGONISTS DO INHIBIT PROLIFERATION OF CLONAL GROWTH OF SCLC AND HAVE BEEN FOUND TO INHIBIT SCLC TUMOR GROWTH IN VIVO. STUDIES WILL BE CONDUCTED TO DESIGN AND SYNTHESIZE MORE STABLE COMPOUNDS FROM THE INHIBITOR STRUCTURES BY CYCLIZATION AND DESCREASING THEIR SUSCEPTIBILITY TO PROTEOLYTIC DEGRADATION. NOVEL GROUPS WILL BE ADDED TO THE ANTAGONISTS TO INCREASE INTERACTION WITH SCLC RECEPTOR. THE EFFECT ON CLONAL GROWTH OF HUMAN SCLC CELLS WILL BE MEASURED AS AN INDICATOR OF IN VIVO ANTI-TUMOR POTENTIAL.
Technology keywords
Not reported